id	sid	eid	entity	type
dti-2343	1	1	dti	ORG
dti-2343	1	2	2022	CARDINAL
dti-2343	1	3	16	CARDINAL
dti-2343	1	4	6-11	CARDINAL
dti-2343	1	5	1177-3928	CARDINAL
dti-2343	1	6	10.33393	CARDINAL
dti-2343	1	7	1177-3928	CARDINAL
dti-2343	1	8	2022	CARDINAL
dti-2343	2	1	4.0	CARDINAL
dti-2343	4	1	silvio zuccarini	PERSON
dti-2343	4	2	fabrizio puce	PERSON
dti-2343	4	3	villa donatello hospital	ORG
dti-2343	4	4	florence italy	ORG
dti-2343	4	5	anti-vegf	PERSON
dti-2343	5	1	anti-vegf	PERSON
dti-2343	6	1	brolucizumab	PERSON
dti-2343	6	2	anti-vegf	ORG
dti-2343	7	1	brolucizumab	PERSON
dti-2343	8	1	nine	CARDINAL
dti-2343	8	2	anti-vegf	PERSON
dti-2343	8	3	ranibizumab	PERSON
dti-2343	8	4	intravitreal brolucizumab	PERSON
dti-2343	8	5	4 weeks	DATE
dti-2343	9	1	one	CARDINAL
dti-2343	9	2	seven	CARDINAL
dti-2343	10	1	up to 12 weeks	DATE
dti-2343	10	2	three	CARDINAL
dti-2343	12	1	anti-vegf	ORG
dti-2343	12	2	the first week	DATE
dti-2343	13	1	brolucizumab	PERSON
dti-2343	14	1	anti-vegf	PERSON
dti-2343	14	2	brolucizumab	PERSON
dti-2343	14	3	september 24, 2021	DATE
dti-2343	14	4	march 16	DATE
dti-2343	14	5	2022	CARDINAL
dti-2343	14	6	march 24	DATE
dti-2343	14	7	2022	CARDINAL
dti-2343	14	8	villa donatello hospital	ORG
dti-2343	14	9	101 50019	CARDINAL
dti-2343	14	10	sesto fiorentino	PERSON
dti-2343	14	11	firenze italy	ORG
dti-2343	15	1	anti-vegf	PERSON
dti-2343	15	2	3,4	CARDINAL
dti-2343	16	1	3,5-9	CARDINAL
dti-2343	17	1	years	DATE
dti-2343	17	2	10	CARDINAL
dti-2343	18	1	srf	ORG
dti-2343	18	2	irf	PERSON
dti-2343	18	3	two years	DATE
dti-2343	18	4	3,11,12	CARDINAL
dti-2343	19	1	around 40%	PERCENT
dti-2343	19	2	3 and 10 years	DATE
dti-2343	19	3	9,13	CARDINAL
dti-2343	20	1	1,2	CARDINAL
dti-2343	21	1	2022	CARDINAL
dti-2343	21	2	16	CARDINAL
dti-2343	21	3	7	CARDINAL
dti-2343	21	4	2022	CARDINAL
dti-2343	22	1	14	CARDINAL
dti-2343	23	1	5 and 10 years	DATE
dti-2343	23	2	41%	PERCENT
dti-2343	23	3	42%	PERCENT
dti-2343	23	4	at least one	CARDINAL
dti-2343	23	5	9,18	CARDINAL
dti-2343	26	1	va	GPE
dti-2343	26	2	20,21	CARDINAL
dti-2343	27	1	at least three	CARDINAL
dti-2343	27	2	monthly	DATE
dti-2343	27	3	ranibizumab	PERSON
dti-2343	27	4	22	CARDINAL
dti-2343	28	1	6 mg	QUANTITY
dti-2343	28	2	®	ORG
dti-2343	28	3	novartis ag	ORG
dti-2343	28	4	basel	GPE
dti-2343	28	5	switzerland	GPE
dti-2343	28	6	anti-vegf	ORG
dti-2343	28	7	23	CARDINAL
dti-2343	29	1	brolucizumab	PERSON
dti-2343	30	1	24	CARDINAL
dti-2343	30	2	brolucizumab	PERSON
dti-2343	30	3	12-week	DATE
dti-2343	30	4	three	CARDINAL
dti-2343	30	5	cst	ORG
dti-2343	30	6	srf/irf	ORG
dti-2343	30	7	48	DATE
dti-2343	30	8	95 weeks	DATE
dti-2343	30	9	23	CARDINAL
dti-2343	31	1	24	CARDINAL
dti-2343	33	1	brolucizumab	PERSON
dti-2343	33	2	25,26	CARDINAL
dti-2343	35	1	1 month	DATE
dti-2343	35	2	italy	GPE
dti-2343	36	1	nine	CARDINAL
dti-2343	37	1	villa donatello hospital	ORG
dti-2343	37	2	florence	GPE
dti-2343	37	3	italy	GPE
dti-2343	38	1	october 2020	DATE
dti-2343	39	1	brolucizumab	PERSON
dti-2343	39	2	first	ORDINAL
dti-2343	40	1	cst	ORG
dti-2343	40	2	irf	PERSON
dti-2343	40	3	srf	ORG
dti-2343	41	1	first	ORDINAL
dti-2343	41	2	two	CARDINAL
dti-2343	41	3	1 ± 1 weeks	DATE
dti-2343	41	4	4 ± 1 weeks	DATE
dti-2343	42	1	three	CARDINAL
dti-2343	43	1	24 hours	TIME
dti-2343	44	1	italian	NORP
dti-2343	46	1	first	ORDINAL
dti-2343	46	2	december 2020	DATE
dti-2343	46	3	1 month	DATE
dti-2343	46	4	4±1 weeks	DATE
dti-2343	47	1	brolucizumab	PERSON
dti-2343	47	2	december 2020	DATE
dti-2343	48	1	srf	ORG
dti-2343	48	2	irf 1 month	PERSON
dti-2343	48	3	brolucizumab injection	PERSON
dti-2343	49	1	srf/irf 1 month	ORG
dti-2343	49	2	1 month	DATE
dti-2343	49	3	1 month	DATE
dti-2343	49	4	first	ORDINAL
dti-2343	49	5	cst	ORG
dti-2343	49	6	1-month	DATE
dti-2343	52	1	cst	ORG
dti-2343	52	2	1 month	DATE
dti-2343	52	3	brolucizumab intravitreal	PERSON
dti-2343	52	4	treatment8	ORG
dti-2343	53	1	2022	CARDINAL
dti-2343	55	1	1177-3928	CARDINAL
dti-2343	55	2	0.05	CARDINAL
dti-2343	56	1	first	ORDINAL
dti-2343	56	2	kaplan-meier	ORG
dti-2343	56	3	two	CARDINAL
dti-2343	57	1	ibm	ORG
dti-2343	57	2	spss	ORG
dti-2343	57	3	26	CARDINAL
dti-2343	58	1	nine	CARDINAL
dti-2343	60	1	i.	PERSON
dti-2343	60	2	brolucizumab	PERSON
dti-2343	60	3	six	CARDINAL
dti-2343	60	4	2	CARDINAL
dti-2343	60	5	2	CARDINAL
dti-2343	60	6	ranibizumab	PERSON
dti-2343	60	7	2	CARDINAL
dti-2343	61	1	ranibizumab	PERSON
dti-2343	62	1	1-month	DATE
dti-2343	62	2	1 week	DATE
dti-2343	62	3	1 month	DATE
dti-2343	62	4	29.1 ±	CARDINAL
dti-2343	62	5	4.6 days	DATE
dti-2343	62	6	24-35	CARDINAL
dti-2343	62	7	first	ORDINAL
dti-2343	63	1	eight	CARDINAL
dti-2343	63	2	88.9%	PERCENT
dti-2343	63	3	seven	CARDINAL
dti-2343	63	4	77.8%	PERCENT
dti-2343	63	5	srf	ORG
dti-2343	63	6	irf	PERSON
dti-2343	63	7	one	CARDINAL
dti-2343	63	8	11.1%	PERCENT
dti-2343	64	1	three	CARDINAL
dti-2343	65	1	cst	ORG
dti-2343	65	2	398.4	CARDINAL
dti-2343	65	3	97.5	CARDINAL
dti-2343	65	4	258.3	CARDINAL
dti-2343	65	5	32.4	CARDINAL
dti-2343	65	6	1 month	DATE
dti-2343	65	7	131.1 μm	CARDINAL
dti-2343	65	8	95%	PERCENT
dti-2343	65	9	46.4-215.8	CARDINAL
dti-2343	65	10	0.007	CARDINAL
dti-2343	66	1	54.4	CARDINAL
dti-2343	66	2	20.1	CARDINAL
dti-2343	66	3	72.8	CARDINAL
dti-2343	66	4	16	CARDINAL
dti-2343	66	5	1 month	DATE
dti-2343	66	6	18.3	CARDINAL
dti-2343	66	7	95%	PERCENT
dti-2343	66	8	6.64-30.02	CARDINAL
dti-2343	66	9	0.011	CARDINAL
dti-2343	67	1	14.2	CARDINAL
dti-2343	67	2	5-23.4	CARDINAL
dti-2343	67	3	3	CARDINAL
dti-2343	67	4	2.03-3.97	CARDINAL
dti-2343	68	1	1	CARDINAL
dti-2343	69	1	three	CARDINAL
dti-2343	69	2	60	CARDINAL
dti-2343	69	3	62	DATE
dti-2343	69	4	92 days	DATE
dti-2343	70	1	oct	DATE
dti-2343	70	2	one	CARDINAL
dti-2343	70	3	brolucizumab	PERSON
dti-2343	70	4	2	CARDINAL
dti-2343	72	1	25,27,28	CARDINAL
dti-2343	73	1	cst	ORG
dti-2343	74	1	approximately 1 month	DATE
dti-2343	74	2	cst	ORG
dti-2343	74	3	29,30	CARDINAL
dti-2343	75	1	brolucizumab	PERSON
dti-2343	75	2	2 weeks	DATE
dti-2343	76	1	more than 4 weeks	DATE
dti-2343	76	2	at least 8 to 12 weeks	CARDINAL
dti-2343	77	1	at least 12 weeks	DATE
dti-2343	77	2	more than 50%	PERCENT
dti-2343	77	3	24	CARDINAL
dti-2343	78	1	12 weeks	DATE
dti-2343	78	2	age (years	DATE
dti-2343	78	3	77.2	CARDINAL
dti-2343	78	4	11.6	CARDINAL
dti-2343	78	5	58	CARDINAL
dti-2343	79	1	77.8	CARDINAL
dti-2343	79	2	54.4	CARDINAL
dti-2343	79	3	20.1	CARDINAL
dti-2343	79	4	cst	ORG
dti-2343	79	5	386.4	CARDINAL
dti-2343	79	6	97.5	CARDINAL
dti-2343	80	1	1 4	CARDINAL
dti-2343	80	2	44.4	CARDINAL
dti-2343	80	3	2 5	DATE
dti-2343	80	4	55.6	CARDINAL
dti-2343	80	5	irf 6	PERSON
dti-2343	80	6	66.7	CARDINAL
dti-2343	80	7	srf 7	ORG
dti-2343	80	8	77.8	CARDINAL
dti-2343	80	9	3	CARDINAL
dti-2343	80	10	33.3	CARDINAL
dti-2343	80	11	3	CARDINAL
dti-2343	80	12	33.3	CARDINAL
dti-2343	80	13	1	CARDINAL
dti-2343	80	14	11.1	CARDINAL
dti-2343	80	15	shrm 1 (	ORG
dti-2343	80	16	11.1	CARDINAL
dti-2343	80	17	min-max	PERSON
dti-2343	80	18	months	DATE
dti-2343	80	19	9.9	CARDINAL
dti-2343	80	20	5.8	CARDINAL
dti-2343	80	21	3	CARDINAL
dti-2343	80	22	5.7	CARDINAL
dti-2343	80	23	3.5	CARDINAL
dti-2343	80	24	2	CARDINAL
dti-2343	80	25	(months	DATE
dti-2343	80	26	2	CARDINAL
dti-2343	80	27	0.7	CARDINAL
dti-2343	80	28	1-3) months	DATE
dti-2343	80	29	3.1	CARDINAL
dti-2343	80	30	1.2	CARDINAL
dti-2343	80	31	2	CARDINAL
dti-2343	81	1	4	CARDINAL
dti-2343	81	2	44.4	CARDINAL
dti-2343	81	3	5	CARDINAL
dti-2343	81	4	55.6	CARDINAL
dti-2343	81	5	cst	ORG
dti-2343	81	6	irf = intraretinal fluid	PERSON
dti-2343	81	7	max = maximum	PERSON
dti-2343	82	1	rpe =	PERSON
dti-2343	82	2	shrm =	ORG
dti-2343	84	1	zuccarini et al	PERSON
dti-2343	84	2	2022	CARDINAL
dti-2343	84	3	16	CARDINAL
dti-2343	84	4	9	CARDINAL
dti-2343	84	5	2022	CARDINAL
dti-2343	86	1	every 8 weeks	DATE
dti-2343	86	2	brolucizumab	PERSON
dti-2343	87	1	va	GPE
dti-2343	88	1	six	CARDINAL
dti-2343	88	2	va	GPE
dti-2343	88	3	26	CARDINAL
dti-2343	88	4	172	CARDINAL
dti-2343	88	5	va	GPE
dti-2343	88	6	one	CARDINAL
dti-2343	88	7	three	CARDINAL
dti-2343	88	8	28	CARDINAL
dti-2343	89	1	two	CARDINAL
dti-2343	89	2	9.9 months	DATE
dti-2343	89	3	at least 2 years	DATE
dti-2343	91	1	3% and 2%	PERCENT
dti-2343	91	2	approximately 1	CARDINAL
dti-2343	91	3	200	CARDINAL
dti-2343	91	4	31	CARDINAL
dti-2343	93	1	1	CARDINAL
dti-2343	93	2	nine	CARDINAL
dti-2343	94	1	50th	ORDINAL
dti-2343	94	2	0 0,0 0,1 0,2 0,3	QUANTITY
dti-2343	94	3	42	CARDINAL
dti-2343	94	4	1210	DATE
dti-2343	95	1	ci de nc e	PERSON
dti-2343	95	2	ac tiv e di se	PERSON
dti-2343	96	1	2	CARDINAL
dti-2343	96	2	90 years old	DATE
dti-2343	96	3	three	CARDINAL
dti-2343	96	4	the previous 9 months	DATE
dti-2343	97	1	brolucizumab injection	PERSON
dti-2343	98	1	1 month	DATE
dti-2343	99	1	2 months	DATE
dti-2343	100	1	brolucizumab intravitreal	PERSON
dti-2343	100	2	2022	CARDINAL
dti-2343	101	1	1177-3928	CARDINAL
dti-2343	101	2	brolucizumab	PERSON
dti-2343	106	1	24,25	CARDINAL
dti-2343	108	1	the first month	DATE
dti-2343	108	2	anti-vegf	NORP
dti-2343	109	1	gabriele massimetti	ORG
dti-2343	109	2	university of pisa	ORG
dti-2343	110	1	corrado minetti	PERSON
dti-2343	110	2	health publishing & services	ORG
dti-2343	110	3	srl	GPE
dti-2343	111	1	1964	DATE
dti-2343	111	2	helsinki	ORG
dti-2343	112	1	comitato etico area vasta centro	ORG
dti-2343	112	2	the careggi university hospital	ORG
dti-2343	112	3	florence	GPE
dti-2343	112	4	italy	GPE
dti-2343	112	5	italian	NORP
dti-2343	117	1	fabrizio puce	PERSON
dti-2343	117	2	alessandro	PERSON
dti-2343	121	1	1	CARDINAL
dti-2343	122	1	grossniklaus	PERSON
dti-2343	123	1	j ophthalmol	PERSON
dti-2343	124	1	2004;137(3):496-503	CARDINAL
dti-2343	125	1	2	CARDINAL
dti-2343	125	2	jaffe gj	PERSON
dti-2343	128	1	2020	DATE
dti-2343	128	2	127(5):616-636	CARDINAL
dti-2343	129	1	3	CARDINAL
dti-2343	130	1	schmidt-erfurth u	PERSON
dti-2343	130	2	waldstein sm	PERSON
dti-2343	132	1	retin eye res	ORG
dti-2343	133	1	2016;50:1	CARDINAL
dti-2343	134	1	crossref	ORG
dti-2343	134	2	4	CARDINAL
dti-2343	134	3	wykoff cc	PERSON
dti-2343	134	4	clark wl	PERSON
dti-2343	134	5	nielsen	PERSON
dti-2343	134	6	brill jv	ORG
dti-2343	134	7	greene ls	PERSON
dti-2343	134	8	heggen	ORG
dti-2343	135	1	anti-vegf	PERSON
dti-2343	136	1	j manag	PERSON
dti-2343	137	1	2018	DATE
dti-2343	138	1	5	CARDINAL
dti-2343	139	1	rasmussen	PERSON
dti-2343	139	2	brandi s	PERSON
dti-2343	142	1	2015;93(7):616	CARDINAL
dti-2343	142	2	620	CARDINAL
dti-2343	143	1	6	CARDINAL
dti-2343	144	1	granero ge	PERSON
dti-2343	144	2	de santis mo	ORG
dti-2343	146	1	2015;253(11):1859-1865	DATE
dti-2343	147	1	7	CARDINAL
dti-2343	148	1	arnold jj	PERSON
dti-2343	148	2	markey cm	PERSON
dti-2343	148	3	kurstjens np	PERSON
dti-2343	148	4	guymer rh	PERSON
dti-2343	149	1	ranibizumab	PERSON
dti-2343	150	1	bmc ophthalmol	ORG
dti-2343	151	1	2016;16(1):31	CARDINAL
dti-2343	151	2	crossref	ORG
dti-2343	151	3	8	CARDINAL
dti-2343	152	1	lanzetta	PERSON
dti-2343	152	2	vision academy	ORG
dti-2343	153	1	anti-vegf	NORP
dti-2343	155	1	2017;255(7):1259-1273	DATE
dti-2343	156	1	crossref	ORG
dti-2343	156	2	9	CARDINAL
dti-2343	157	1	gillies m	PERSON
dti-2343	157	2	arnold j	PERSON
dti-2343	157	3	bhandari s	PERSON
dti-2343	157	4	ten-year	DATE
dti-2343	157	5	two	CARDINAL
dti-2343	158	1	j ophthalmol	PERSON
dti-2343	159	1	2020;210:116-124	CARDINAL
dti-2343	160	1	10	CARDINAL
dti-2343	161	1	chandra s	PERSON
dti-2343	161	2	menon	GPE
dti-2343	161	3	ten-year	DATE
dti-2343	163	1	2020;34(10):1888-1896	DATE
dti-2343	164	1	11	CARDINAL
dti-2343	165	1	brown dm	PERSON
dti-2343	165	2	chong v	PERSON
dti-2343	165	3	1	CARDINAL
dti-2343	165	4	2	CARDINAL
dti-2343	166	1	intravitreal	PERSON
dti-2343	166	2	vegf trap-eye	PERSON
dti-2343	168	1	2012;119(12	CARDINAL
dti-2343	169	1	12	CARDINAL
dti-2343	170	1	guymer rh	PERSON
dti-2343	170	2	markey cm	PERSON
dti-2343	170	3	mcallister il	PERSON
dti-2343	171	1	ranibizumab	PERSON
dti-2343	171	2	24-month	DATE
dti-2343	173	1	2019;126(5):723-734	CARDINAL
dti-2343	174	1	13	CARDINAL
dti-2343	175	1	bhandari s	PERSON
dti-2343	175	2	nguyen v	PERSON
dti-2343	175	3	arnold j	PERSON
dti-2343	178	1	2020;127(3):369-376	CARDINAL
dti-2343	179	1	14	CARDINAL
dti-2343	180	1	essex rw	PERSON
dti-2343	180	2	nguyen v	PERSON
dti-2343	180	3	walton	GPE
dti-2343	183	1	2016	CARDINAL
dti-2343	184	1	123(11):2393-2400	DATE
dti-2343	185	1	crossref	ORG
dti-2343	185	2	15	CARDINAL
dti-2343	186	1	nguyen v	PERSON
dti-2343	186	2	fraser-bell s	ORG
dti-2343	188	1	3 months	DATE
dti-2343	190	1	2019;3(8	DATE
dti-2343	190	2	623	CARDINAL
dti-2343	191	1	16	CARDINAL
dti-2343	192	1	rusakevich am	PERSON
dti-2343	192	2	zhou	PERSON
dti-2343	192	3	wong tp	PERSON
dti-2343	192	4	quarterly	DATE
dti-2343	194	1	2019;50(9	CARDINAL
dti-2343	194	2	crossref pubmed https://doi.org/10.1016/j.ajo.2003.09.042	ORG
dti-2343	194	3	2022	CARDINAL
dti-2343	194	4	16	CARDINAL
dti-2343	194	5	11	CARDINAL
dti-2343	194	6	2022	CARDINAL
dti-2343	195	1	17	CARDINAL
dti-2343	196	1	monés j	PERSON
dti-2343	196	2	singh	GPE
dti-2343	196	3	liu x	PERSON
dti-2343	196	4	10 years	DATE
dti-2343	198	1	2020;243(1):1-8	CARDINAL
dti-2343	199	1	18	CARDINAL
dti-2343	200	1	gillies mc	PERSON
dti-2343	203	1	2015;122(9):1837-1845	DATE
dti-2343	204	1	19	CARDINAL
dti-2343	205	1	binder s. loss	PERSON
dti-2343	205	2	anti-vegf	PERSON
dti-2343	208	1	2012;96(1):1	CARDINAL
dti-2343	209	1	20	CARDINAL
dti-2343	210	1	chakravarthy u	GPE
dti-2343	212	1	2019;3(1):8-15.e1	CARDINAL
dti-2343	212	2	crossref	ORG
dti-2343	212	3	21	CARDINAL
dti-2343	213	1	nguyen cl	PERSON
dti-2343	213	2	gillies mc	PERSON
dti-2343	213	3	nguyen v	PERSON
dti-2343	217	1	2019;126(5):735-742	CARDINAL
dti-2343	218	1	22	CARDINAL
dti-2343	219	1	salcedo-villanueva g	ORG
dti-2343	219	2	feria-anzaldo	TIME
dti-2343	219	3	romo-aguas jc	PERSON
dti-2343	220	1	anti-vegf	PERSON
dti-2343	220	2	ranibizumab	PERSON
dti-2343	222	1	2019;39(9):20232031	CARDINAL
dti-2343	223	1	crossref	ORG
dti-2343	223	2	23	CARDINAL
dti-2343	224	1	dugel pu	PERSON
dti-2343	224	2	singh	GPE
dti-2343	224	3	koh	PERSON
dti-2343	224	4	ninetysix-week	DATE
dti-2343	224	5	3	CARDINAL
dti-2343	226	1	2021;128(1):89-99	DATE
dti-2343	227	1	crossref	ORG
dti-2343	227	2	24	CARDINAL
dti-2343	228	1	dugel pu	PERSON
dti-2343	228	2	koh	PERSON
dti-2343	229	1	3	CARDINAL
dti-2343	231	1	2020;127(1):72-84	CARDINAL
dti-2343	232	1	crossref	ORG
dti-2343	232	2	25	CARDINAL
dti-2343	233	1	kumar n	PERSON
dti-2343	233	2	brolucizumab	PERSON
dti-2343	235	1	2021;35(4):10451047	CARDINAL
dti-2343	236	1	26	CARDINAL
dti-2343	237	1	lee s	PERSON
dti-2343	238	1	j. 2020;13:145-152	ORG
dti-2343	239	1	27	CARDINAL
dti-2343	240	1	seguin-greenstein s	PERSON
dti-2343	241	1	j ophthalmol	PERSON
dti-2343	242	1	2016;2016:4095852	ORDINAL
dti-2343	243	1	28	CARDINAL
dti-2343	244	1	enríquez ab	ORG
dti-2343	245	1	brolucizumab	PERSON
dti-2343	246	1	jama ophthalmol	PERSON
dti-2343	248	1	29	CARDINAL
dti-2343	249	1	bontzos g	PERSON
dti-2343	249	2	ranibizumab anti-vegf	PERSON
dti-2343	249	3	oct	DATE
dti-2343	251	1	2020;4(12):1138-1145	CARDINAL
dti-2343	252	1	30	CARDINAL
dti-2343	253	1	zola m	PERSON
dti-2343	254	1	anti-vegf	PERSON
dti-2343	256	1	2021	CARDINAL
dti-2343	256	2	31	CARDINAL
dti-2343	257	1	monés j	PERSON
dti-2343	257	2	srivastava sk	PERSON
dti-2343	257	3	jaffe gj	PERSON
dti-2343	257	4	brolucizumab	PERSON
dti-2343	259	1	2021	CARDINAL
dti-2343	259	2	jul;128(7):1050-1059	ORG
dti-2343	260	1	https://www.ncbi.nlm.nih.gov/pubmed/31743912	DATE
dti-2343	260	2	https://www.ncbi.nlm.nih.gov/pubmed/26096346	DATE
dti-2343	260	3	https://doi.org/10.1136/bjophthalmol-2011-301236	PERSON
dti-2343	261	1	https://doi.org/10.2147/imcrj.s252260 https://www.ncbi.nlm.nih.gov/pubmed/32494207 https://doi.org/10.1155/2016/4095852	PERSON